As founders, we work side-by-side with our entrepreneurs to
build companies around innovative science.

All

    TOGGLE ALL / NONE

main-image-numerate-FPO
Numerate

Small molecule
drug design
using statistical modeling

decode chromosome image copy
deCODE genetics

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

main-image-rodin-FPO
Rodin Therapeutics

Behavioral epigenetic therapy
for cognitive
and neurodegenerative disease

momenta logo blue green
Momenta Pharmaceuticals

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

main-image-ataxion-FPO
Ataxion

Therapies for rare,
debilitating, and underserved
neurological diseases

main-image-raze
Raze Therapeutics

Cancer therapeutics
targeting anabolic
tumor metabolism

Eagalet-Mftng-image_edit
Egalet Corporation

Tamper resistant therapies for
chronic pain – IPO Feb 2014
(NASDAQ: EGLT)

main-image-annovation
Annovation Biopharma

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

main-image-f-star
F-Star Alpha Limited

Bispecific antibodies
to improve the treatment
of serious diseases

zafgen-full
Zafgen

First-in-class therapies for severe
obesity and rare genetic conditions –
IPO June 2014 (NASDAQ: ZFGN)

main-image-costim
CoStim Pharmaceuticals

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Arteaus_portfolio
Arteaus Therapeutics

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

main-image-surface
Surface Oncology

Cancer immunotherapies
at the interface of
innate & adaptive immunity

main-image-avila
Avila Therapeutics

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

arrow hep c image for website
Arrow Therapeutics

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

micromet ALL-328-precursor-b-cell cropped
Micromet

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

Nimbus - gallery view
Nimbus Therapeutics

Breakthrough computer-aided
drug design
for transformative medicines

main-image-quartet
Quartet Medicine

Biomarker-guided therapies
for chronic pain
and inflammation

Actelion PAH for website
Actelion

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

main-image-unum-FPO
Unum Therapeutics

Universal
cell-based
cancer immunotherapy

main-image-vitae
Vitae Pharmaceuticals

Novel therapeutics using proprietary
computational chemistry –
IPO Sept 2014 (NASDAQ: VTAE)

main-image-intellia-FPO
Intellia Therapeutics

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

main-image-infacare-FPO
Infacare

Proprietary pharmaceuticals
for neonatal care
and pediatrics

Bicycle
Bicycle Therapeutics

Novel bicyclic peptides (bicycles)
and bicycle drug conjugates
for cancer

Horizon2
Horizon Pharma

Specialty pharma focused on
chronic inflammatory diseases –
IPO July 2011 (NASDAQ: HZNP)

novexel BetaLactamaseComplex_1 for website
Novexel

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

delinia-bio-t-cell-600x506
Delinia

Novel biologic
therapeutics for
autoimmune diseases

hucal-platinum-072_1 2 - web crop
MorphoSys

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

main-image-navitor-FPO
Navitor Pharmaceuticals

Novel therapeutics
targeting
diseases of aging

Harbor4b
Harbour Antibodies

Mouse platforms
for the generation of
fully human antibodies

main-image-mnemosyne-FPO
Luc Therapeutics

Novel therapeutics for
schizophrenia and other
severe psychiatric diseases

Atlas600x506_forweb
AVROBIO

Cell and gene therapies
for rare diseases
and cancer

main-image-jenavalve
JenaValve

Minimally invasive
heart valve
devices

REPLIMUNE MAIN IMAGE-01
Replimune

Next-generation oncolytic
immunotherapies for
cancer treatment

crucell polio virus image
Crucell

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

main-image-miragen-FPO
miRagen Therapeutics

Innovative
micro-RNA-based
therapies

main-image-lti-FPO
Lysosomal Therapeutics, Inc.

Discovering new medicines
for severe
neurodegenerative diseases

ALNY-lab1 2 - cropped for web 2
Alnylam Pharmaceuticals

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

main-image-rana
RaNA Therapeutics

First-in-class
RNA therapies
for severe genetic diseases

Stromedix
Stromedix

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

Print
Exelixis

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

main-image-padlock
Padlock Therapeutics

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

U3 website header image 4 cropped for web
U3 Pharma

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

arqule c-met image for website
ArQule

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

Spero---Fotolia_56849944_edit
Spero Therapeutics

Novel therapies
for severe, highly drug-resistant
bacterial infections

obsidian-brand-image-final
Obsidian Therapeutics

New class of
regulated cell and
gene therapies

Adnexus logo crop
Adnexus Therapeutics

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007

IMF-AtlasRectangle 600w
IFM Therapeutics

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

main-image-synlogic
Synlogic

Next generation
synthetic biology platform
for novel therapeutics